Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

338
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
338
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

226
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
226
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

375
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
375
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

426
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
426
Inhaled Medications01:23

Inhaled Medications

342
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
342

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?

European journal of neurology·2026
Same author

Cup-to-Disc Ratio Is Associated with Disability in Multiple Sclerosis: A Combined OCT and Subjective Visual Vertical Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Investigating the feasibility and acceptability of the TeleRehabilitation of balance clinical and economic Decision Support System (TeleRehaB DSS) in adults at risk of falls: study protocol for a multicentre clinical trial.

BMJ open·2026
Same author

Editorial: Mechanisms of functional dizziness: a window for understanding space-motion cognition.

Frontiers in neurology·2026
Same author

Down-sloping high-frequency audiometric findings in ENT-MS-12 auditory screen-positive patients with relapsing-remitting multiple sclerosis: A pilot case series.

Multiple sclerosis and related disorders·2026
Same author

Communication, expectancy, and placebo response in clinical trial design.

The lancet. Psychiatry·2026

Related Experiment Video

Updated: Aug 8, 2025

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

13.3K

Intratympanic corticosteroids for Ménière's disease.

Katie E Webster1, Ambrose Lee2, Kevin Galbraith1

  • 1Cochrane ENT, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

The Cochrane Database of Systematic Reviews
|February 27, 2023
PubMed
Summary
This summary is machine-generated.

Intratympanic corticosteroids may offer little benefit for Ménière

More Related Videos

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus
06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus

Published on: February 27, 2018

8.7K
Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

1.4K

Related Experiment Videos

Last Updated: Aug 8, 2025

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

13.3K
A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus
06:55

A Surgical Procedure for the Administration of Drugs to the Inner Ear in a Non-Human Primate Common Marmoset Callithrix jacchus

Published on: February 27, 2018

8.7K
Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

1.4K

Area of Science:

  • Otolaryngology
  • Neurology
  • Pharmacology

Background:

  • Ménière's disease is characterized by recurrent vertigo, hearing loss, and tinnitus.
  • Intratympanic corticosteroids are used to treat Ménière's disease, but their efficacy is unclear.
  • The underlying causes of Ménière's disease and the mechanism of this treatment remain unknown.

Purpose of the Study:

  • To evaluate the benefits and harms of intratympanic corticosteroids compared to placebo or no treatment for Ménière's disease.
  • To assess the impact on vertigo attacks, hearing, tinnitus, and quality of life.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
  • Included 10 studies with 952 adult participants diagnosed with Ménière's disease.
  • Primary outcomes included vertigo improvement, change in vertigo, and serious adverse events.

Main Results:

  • Intratympanic corticosteroids showed little to no difference in vertigo improvement at 6-12 months and >12 months follow-up (low-certainty evidence).
  • A slight reduction in vertigo episode frequency was observed (low-certainty evidence), but with caution due to unpublished data.
  • Evidence regarding serious adverse events was very uncertain (very low-certainty evidence).

Conclusions:

  • The evidence for intratympanic corticosteroids in treating Ménière's disease is uncertain due to a limited number of studies and concerns about publication bias.
  • The certainty of evidence for most outcomes was low to very low, indicating low confidence in the reported effects.
  • Further research with a consensus on core outcome sets is needed to guide future studies and enable reliable meta-analyses.